Menu

Markets

Research

News

Learn
Paper trading
AI Chat
WatchlistsPortfoliosAlerts
Sign in

Sutro Biopharma, Inc. STRO

Set alert

Price alert · STRO

All alert types
9.10 USD -0.04 -0.44%

At close · Oct 30

9.10 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
9.06 × 2
Ask
9.13 × 2
8.80 Day range 9.40
7.30 52-week range 40.91
YTD
-21.35%
1 year
-21.55%
Open
9.10
Prev close
9.14
Mkt cap
150.89M
Vol
122.29K
Avg vol
313.94K
EPS
-17.28
P/E
0.00
Div yield
0.00%
More statistics
Low
8.80
High
9.40
Forward P/E
-0.63
Beta
0.00
Short ratio
2.47
Inst. own
77.14%
Dividend
0.00
Ex-div date
Earnings
Aug 13, 2024
50-d avg
3.12
200-d avg
3.73
1y target
11.50

3M chart

Chart tools
Interval
1m5m15m30m

Signals (11)
NameDateAgo
RSI: OversoldOct 21, 20261 week ago
MACD: Sell SignalOct 13, 20262 weeks ago
RSI: OversoldOct 9, 20263 weeks ago
RSI: OversoldOct 2, 20264 weeks ago
MACD: Buy SignalSep 25, 20261 month ago
RSI: OversoldSep 23, 20261 month ago
RSI: OversoldSep 10, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
MACD: Buy SignalAug 26, 20262 months ago
MACD: Sell SignalAug 13, 20262 months ago
MACD: Buy SignalJul 31, 20263 months ago

Financial health

Altman Z-Score

-8.69 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

3 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

FMP rating

C2 / 5 overall

  • DCF 1
  • Return on Equity 5
  • Return on Assets 1
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E -0.5×
FY 2016: 3.9×FY 2017: -5.4×FY 2018: -5.8×FY 2019: -4.5×FY 2020: -21.9×FY 2021: -6.5×FY 2022: -3.4×FY 2023: -2.4×FY 2024: -0.6×FY 2025: -0.5×
FY 2016 5y median -2.4× FY 2025
P/S 1.0×
FY 2016: 0.1×FY 2017: 2.1×FY 2018: 5.4×FY 2019: 5.9×FY 2020: 16.6×FY 2021: 11.1×FY 2022: 6.0×FY 2023: 1.7×FY 2024: 2.3×FY 2025: 1.0×
FY 2016 5y median 2.3× FY 2025
P/B -0.7×
FY 2016: -0.1×FY 2017: -1.0×FY 2018: 1.6×FY 2019: 2.6×FY 2020: 2.1×FY 2021: 2.7×FY 2022: 1.9×FY 2023: 1.7×FY 2024: 3.2×FY 2025: -0.7×
FY 2016 5y median 1.9× FY 2025
P/FCF -0.5×
FY 2016: -0.4×FY 2017: -2.6×FY 2018: 18.5×FY 2019: -3.7×FY 2020: -9.4×FY 2021: -7.1×FY 2022: -95.1×FY 2023: -2.2×FY 2024: -0.7×FY 2025: -0.5×
FY 2016 5y median -2.2× FY 2025
EV/EBITDA -0.4×
FY 2016: -0.5×FY 2017: -7.0×FY 2018: -2.9×FY 2019: -5.5×FY 2020: -22.1×FY 2021: -7.3×FY 2022: -3.9×FY 2023: -3.3×FY 2024: 0.1×FY 2025: -0.4×
FY 2016 5y median -3.3× FY 2025
EV/Sales 0.5×
FY 2016: -0.1×FY 2017: 1.9×FY 2018: 2.5×FY 2019: 6.0×FY 2020: 12.3×FY 2021: 11.5×FY 2022: 6.2×FY 2023: 1.4×FY 2024: -0.4×FY 2025: 0.5×
FY 2016 5y median 1.4× FY 2025
FCF Yield -182.0%
FY 2016: -261.7%FY 2017: -38.0%FY 2018: 5.4%FY 2019: -27.1%FY 2020: -10.6%FY 2021: -14.1%FY 2022: -1.1%FY 2023: -44.9%FY 2024: -137.7%FY 2025: -182.0%
FY 2016 5y median -44.9% FY 2025

Profitability

Gross Margin 92.9%
FY 2016: 27.1%FY 2017: -0.3%FY 2018: -41.2%FY 2019: 100.0%FY 2020: -80.1%FY 2021: 84.2%FY 2022: 87.8%FY 2023: 95.6%FY 2024: 88.4%FY 2025: 92.9%
FY 2016 5y median 88.4% FY 2025
Operating Margin -102.4%
FY 2016: 2.3%FY 2017: -37.2%FY 2018: -96.9%FY 2019: -129.8%FY 2020: -166.3%FY 2021: -159.2%FY 2022: -190.3%FY 2023: -58.1%FY 2024: -384.3%FY 2025: -102.4%
FY 2016 5y median -159.2% FY 2025
Net Margin -186.5%
FY 2016: 2.8%FY 2017: -38.1%FY 2018: -91.9%FY 2019: -130.4%FY 2020: -75.2%FY 2021: -170.6%FY 2022: -175.9%FY 2023: -69.5%FY 2024: -366.6%FY 2025: -186.5%
FY 2016 5y median -175.9% FY 2025
ROE 144.3%
FY 2016: -1.9%FY 2017: 18.1%FY 2018: -26.8%FY 2019: -57.0%FY 2020: -9.7%FY 2021: -41.8%FY 2022: -54.9%FY 2023: -71.4%FY 2024: -510.0%FY 2025: 144.3%
FY 2016 5y median -54.9% FY 2025
ROIC -98.5%
FY 2016: 7.1%FY 2017: -82.4%FY 2018: -19.4%FY 2019: -44.6%FY 2020: -19.5%FY 2021: -31.8%FY 2022: -35.6%FY 2023: -23.0%FY 2024: -90.7%FY 2025: -98.5%
FY 2016 5y median -35.6% FY 2025
ROA -109.9%
FY 2016: 2.5%FY 2017: -48.3%FY 2018: -15.8%FY 2019: -35.6%FY 2020: -8.2%FY 2021: -30.9%FY 2022: -29.3%FY 2023: -22.7%FY 2024: -58.7%FY 2025: -109.9%
FY 2016 5y median -30.9% FY 2025

Growth (YoY)

Revenue 65.2%
FY 2016: 0.0%FY 2017: -13.4%FY 2018: -25.7%FY 2019: 11.2%FY 2020: -0.0%FY 2021: 44.8%FY 2022: 9.5%FY 2023: 126.8%FY 2024: -59.6%FY 2025: 65.2%
FY 2016 FY 2025
Operating Income 56.0%
FY 2016: 0.0%FY 2017: -1512.9%FY 2018: -93.1%FY 2019: -49.0%FY 2020: -28.1%FY 2021: -38.7%FY 2022: -30.9%FY 2023: 30.8%FY 2024: -167.1%FY 2025: 56.0%
FY 2016 FY 2025
EPS (diluted) 24.0%
FY 2016: 0.0%FY 2017: -172.8%FY 2018: 45.2%FY 2019: -57.8%FY 2020: 59.3%FY 2021: -131.3%FY 2022: -2.6%FY 2023: 24.3%FY 2024: -66.3%FY 2025: 24.0%
FY 2016 FY 2025
Free Cash Flow 8.1%
FY 2016: 0.0%FY 2017: -130.2%FY 2018: 127.5%FY 2019: -715.7%FY 2020: -9.4%FY 2021: -29.5%FY 2022: 95.6%FY 2023: -2590.4%FY 2024: -67.9%FY 2025: 8.1%
FY 2016 FY 2025

Financial Health

Current Ratio 2.0×
FY 2016: 1.0×FY 2017: 0.8×FY 2018: 5.8×FY 2019: 3.9×FY 2020: 12.8×FY 2021: 5.2×FY 2022: 5.3×FY 2023: 4.5×FY 2024: 2.6×FY 2025: 2.0×
FY 2016 5y median 4.5× FY 2025
Quick Ratio 2.0×
FY 2016: 1.0×FY 2017: 0.8×FY 2018: 5.8×FY 2019: 3.9×FY 2020: 12.8×FY 2021: 5.2×FY 2022: 5.3×FY 2023: 4.5×FY 2024: 2.6×FY 2025: 2.0×
FY 2016 5y median 4.5× FY 2025
Debt / Equity -0.1×
FY 2016: -0.0×FY 2017: -0.1×FY 2018: 0.1×FY 2019: 0.1×FY 2020: 0.1×FY 2021: 0.2×FY 2022: 0.3×FY 2023: 0.2×FY 2024: 0.5×FY 2025: -0.1×
FY 2016 5y median 0.2× FY 2025
Net Debt / EBITDA 0.3×
FY 2016: -1.4×FY 2017: 0.5×FY 2018: 3.4×FY 2019: -0.1×FY 2020: 7.6×FY 2021: -0.3×FY 2022: -0.1×FY 2023: 0.5×FY 2024: 0.9×FY 2025: 0.3×
FY 2016 5y median 0.3× FY 2025
Interest Coverage -2.7×
FY 2016: 0.0×FY 2017: -28.0×FY 2018: -23.3×FY 2019: -12.8×FY 2020: -17.9×FY 2021: -31.4×FY 2022: -38.5×FY 2023: -3.8×FY 2024: -7.7×FY 2025: -2.7×
FY 2016 5y median -7.7× FY 2025

Dividends

Dividend Yield 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31